61 results about "Post-herpetic neuralgia" patented technology

The present invention is directed generally to systems, devices and methods for direct delivery of agents, e.g., pharmaceutical agents, to target spinal and neuronal anatomies, e.g., the dorsal root ganglia (DRG), for the treatment of various disorders, particularly pain and pain related disorders, such as chronic itch, sensory disorders, multiple sclerosis, post-herpetic neuralgia and the like. The system, devices and methods of the invention encompass the agents to be delivered to the target anatomy alone or in combination with electrical stimulation. The delivery device and systems and methods as disclosed herein place the distal end of the delivery element, which comprises at least one agent delivery structure, and optionally at least one electrode, in close proximity, or in contact with or next to the target spinal anatomy, e.g., DRG. A variety of agents can be delivered using the device, including sodium channel blockers, biologics, neuroinflammatory modulators, toxins etc., to selectively neuromodulate the neurons. Agent delivery and / or electrical stimulation can be automated and / or can be controlled automatically or by a pre-determined program, or by a patient control pump (PCA).

Methods for treating neurological or neuropsychiatric diseases or disorders in humans by administering to the human a therapeutically effective dose of specific biologics are presented. The biologics of consideration include antagonists of tumor necrosis factor or of interleukin-1. The administration of these biologics is performed by specific methods, most, but not all of which fall into the category of anatomically localized administration designed for perispinal use. Anatomically localized administration involving perispinal use includes, but is not limited to the subcutaneous, intramuscular, interspinous, epidural, peridural, parenteral or intrathecal routes. Additonally, intranasal administration is discussed as a method to provide therapeutic benefit. The clinical conditions of consideration include, but are not limited to the following: diseases of the brain, including neurodegenerative diseases such as Alzheimer's Disease and Parkinson's Disease; migraine headache; spinal radiculopathy associated with intervertebral disc herniation, post-herpetic neuralgia, reflex sympathethic dystrophy, neuropathic pain, vertebral disc disease, low back pain, amyotrophic lateral sclerosis, chronic fatigue syndrome; and neuropsychiatric diseases, including bipolar affective disorder, anorexia nervosa, nicotine withdrawal, narcotic addiction, alcohol withdrawl, postpartum depression, and schizoaffective illness.

An apparatus for use in peripheral nerve field stimulation (PNFS) whereby a plurality of curved introducer needles, of varying curvatures, are provided to permit the physician to best locate the region of oligodendrocytes that contain the A Beta fibers by matching the lumbar lordosis. A wing device is also provided that is attachable to the hub of the curved needle introducer which gives the physician better ability to maneuver the needle during insertion as well as permitting tenting of the skin. The invention benefits a large number of painful disorders arising from pathology in the cervical, thoracic, and lumbar spine. In addition, this invention can also help a large number of other conditions including but not limited to failed back surgery syndrome / post-laminectomy pain, occipital / suboccipital headaches, scar pain, post herpetic neuralgia pain, mononeuritis multiplex, and pain following joint surgery (e.g., knee, hip, shoulder).

A tolperisone-related compound or a compound of Formula Z is administered for the prevention and treatment of periodic paralyses and myotonias of several types, long QT syndrome, Brugada syndrome, malignant hyperthermia, myasthenia, epilepsy, ataxia, migraine, Alzheimer's Disease, Parkinson's Disease, schizophrenia, and hyperekplexia, neuropathic pain, and pain associated with nervous system disorders including, but not limited to, painful diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, complex regional pain syndrome, Guillain-Barre syndrome (GBS), Charcot-Marie-Tooth (CMT) disease, complex regional pain syndrome, type 1 (CRPS-1), ischemic neuropathy, fibromyalgia, chronic fatigue syndrome, painful spasticities, and other nervous system disorders that have pain as an attendant sign and / or symptom.

Methods and compositions are offered for reducing nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia), where intradermal delivery of lidocaine is maintained for a predetermined period of time. The lidocaine appears to specifically affect the damaged nerve fibers, while leaving the undamaged and normal nerve fibers with retention of response to other stimuli. Lidocaine formulations are provided which allow for the necessary dosage of the lidocaine in the dermis during the period of treatment. The formulation may be covered with an occlusive or non-occlusive dressing, which protects the lidocaine formulation from mechanical removal and enhances the transport of the lidocaine into the dermis. Long term relief is realized after maintenance of the administration of lidocaine has been terminated.

Methods for treating neurological or neuropsychiatric diseases or disorders in humans by administering to the human a therapeutically effective dose of specific biologics are presented. The biologics of consideration include antagonists of tumor necrosis factor or of interleukin-1. The administration of these biologics is performed by specific methods, most, but not all of which fall into the category of anatomically localized administration designed for perispinal use. Anatomically localized administration involving perispinal use includes, but is not limited to the subcutaneous, intramuscular, interspinous, epidural, peridural, parenteral or intrathecal routes. Additonally, intranasal administration is discussed as a method to provide therapeutic benefit. The clinical conditions of consideration include, but are not limited to the following: diseases of the brain, including neurodegenerative diseases such as Alzheimer's Disease and Parkinson's Disease; migraine headache; spinal radiculopathy associated with intervertebral disc herniation, post-herpetic neuralgia, reflex sympathethic dystrophy, neuropathic pain, vertebral disc disease, low back pain, amyotrophic lateral sclerosis, chronic fatigue syndrome; and neuropsychiatric diseases, including bipolar affective disorder, anorexia nervosa, nicotine withdrawal, narcotic addiction, alcohol withdrawl, post-partum depression, and schizoaffective illness.

Pharmaceutical formulations for treating neurological diseases are described, wherein the formulations comprise a pharmaceutically active agent-transport moiety complex. The formulations are suitable for administration via an intranasal route. Neurological diseases and conditions are associated with reduced brain insulin signaling (i.e., CNS insulin insensitivity), reduced dopaminergic signaling, reduced serotonergic signaling, reduced cholinergic signaling, or reduced GABAergic signaling, and include Alzheimer's disease, Parkinson's disease, epilepsy, neuropathic pain, fibromyalgia, post-herpetic neuralgia, insomnia, or anxiety. Neurological diseases also include cancers of the central nervous system (CNS).

The present invention is directed generally to systems, devices and methods for direct delivery of agents, e.g., pharmaceutical agents, to target spinal and neuronal anatomies, e.g., the dorsal root ganglia (DRG), for the treatment of various disorders, particularly pain and pain related disorders, such as chronic itch, sensory disorders, multiple sclerosis, post-herpetic neuralgia and the like. The system, devices and methods of the invention encompass the agents to be delivered to the target anatomy alone or in combination with electrical stimulation. The delivery device and systems and methods as disclosed herein place the distal end of the delivery element, which comprises at least one agent delivery structure, and optionally at least one electrode, in close proximity, or in contact with or next to the target spinal anatomy, e.g., DRG. A variety of agents can be delivered using the device, including sodium channel blockers, biologics, neuroinflammatory modulators, toxins etc., to selectively neuromodulate the neurons. Agent delivery and / or electrical stimulation can be automated and / or can be controlled automatically or by a pre-determined program, or by a patient control pump (PCA).

The invention discloses a lyrica preparation method. Lyrica is an analogue of a mammal neurotransmitter of Lambda-propalanine, is clinically used for curing diabetic peripheral neuralgia and post-herpetic neuralgia and adjunctively treating partial adult seizure. The Lyrica is synthesized through using S-(+)-leucine as a raw material by a chemical method without decomposition, and has the advantages of easily obtained raw materials, less reaction steps, mild reaction conditions, high reaction yield, and the like.

The present disclosure relates to substituted amide compounds that are inhibitors of Fatty Acid Amide Hydrolase (FAAH), their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them. These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of Fatty Acid Amide Hydrolase (FAAH), such as pain including acute and post operative pain, chronic pain, cancer pain, cancer chemotherapy induced pain, neuropathic pain, nociceptive pain, inflammatory pain, back pain, pain due to disease of various origin such as: diabetic neuropathy, neurotropic viral disease including human immunodeficient virus (HIV), herpes zoster such as post herpetic neuralgia; polyneuropathy, neurotoxicity, mechanical nerve injury, carpal tunnel syndrome, immunologic mechanisms like multiple sclerosis; sleep disorders, anxiety and depression disorders, inflammatory disorders, weight and eating disorders, Parkinson's disease, addiction, spasticity, hypertension or other disorders. The disclosure also relates to the process of preparation of the amide compounds. Formula (1). The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.

The present invention relates to methods of treating diabetic neuropathic pain comprising administering piperidine derivatives, such as 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-N-(2-oxo-2,3-dihydro-benzoxazol-6-yl)acetamide, and pharmaceutically acceptable salts thereof. Methods of treating post-herpetic neuralgia, chronic lower back pain, osteoarthritis and acute inflammatory pain are described.

The invention relates to a formula for a traditional Chinese medicine for external administration, which cures Postherpetic neuralgia. The formula comprises the following components by percentage: 16% of fossilia spiriferis, 14% of rhubarb, 9.5% of frankincense, 9.5% of myrrh, 9.5% of notoginseng, 6% of garter snake, 6% of dragon's blood, 6% of periostracum cicadae, 6% of processed radix aconiti, 5.5% of processed radix aconiti kusnezoffii, 6% of angelica dahurica and 6% of borneol. The preparation method comprises the following steps: grinding rhubarb, frankincense, myrrh, notoginseng, dragon's blood and angelica dahurica into coarse powder; soaking in ethanol; percolating to obtain the medicament liquid; dissolving borneol with 75% of ethanol; and mixing the three liquids. The formula allows the medicine to permeate into the skin so as to relieve and dispel neuralgia, has the advantages of convenient administration, no side effect and significant curative effect and is of great popularization and application values.

The present invention relates to methods of treating diabetic neuropathic pain comprising administering piperidine derivatives, such as 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-N-(2-oxo-2,3-dihydro-benzoxazol-6-yl)acetamide, and pharmaceutically acceptable salts thereof. Methods of treating post-herpetic neuralgia, chronic lower back pain, osteoarthritis and acute inflammatory pain are described.

The present invention provides medicinal agents that are useful for the prevention or treatment of neuropathic pain which comprises as an active ingredient a β2 adrenoceptor stimulant. In addition, the present invention provides formulations for the prevention or treatment of neuropathic pain such as painful diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, or postoperative or traumatic chronic pain, that are characterized by the use in combination of an α2-adrenoceptor stimulant and a β2-adrenoceptor stimulant, or by containing a compound that has both α2-adrenoceptor stimulation and β2-adrenoceptor stimulation activities as an active ingredient or the like.

Provided are methods for treating, reducing, alleviating, and / or inhibiting neuropathic pain by orally, intravenously or intrathecally administering an effective amount of an inhibitor of soluble epoxide hydrolase (“sEH”), to a patient in need thereof. The neuropathic pain treated is selected from the group consisting of post-herpetic neuralgia, trigeminal neuralgia, focal peripheral nerve injury, and anesthesia dolorosa, central pain due to stroke or mass lesion, spinal cord injury, or multiple sclerosis, and peripheral neuropathy due to diabetes, HIV, or chemotherapy.

The invention relates to a Chinese traditional medicine used for treating postherpetic neuralgia, which aims at developing a Chinese traditional medicine used for treating postherpetic neuralgia by adopting the theory of Chinese traditional medicine. The formula of the invention includes magnet, turmeric, dyers woad leaf, radix isatidis, cape jasmine fruit, radix scutellariae, Chinese thorowax root, rehmanniae praeparatum, semen plantaginis, liquoric root, angelica and white paeony root. The invention has the advantages of low price, good curative effect, being not easy to recur and extremely good social and economic benefits. The total effective rate of the medicine of the invention can reach more than 94.70%.

Nitrone, nitroso, and nitroxide spintraps and spin labels and their reduction products are claimed for the prevention and treatment of fibrocystic disease of breast, premenstrual dysphoric syndrome and associated symptomology, prevention and treatment of migraine headache, cyclic vomiting syndrome, rectal hemorrhoids, trigeminal neuralgia, peripheral vascular disease, influenza, peridontitis and gingivitis, herpes zoster, herpes simplex, and post-herpetic neuralgia.

The invention relates to a traditional Chinese medicine for oral administration, which cures post-herpetic neuralgia, and the preparation method thereof. The formula of the traditional Chinese medicine comprises the following components by percentage: 16% of alcohol processed radix paeoniae alba, 8% of liquorice, 6% of rhizoma atractylodis macrocephalae, 12% of isatis root, 12% of glabrous greenbrier rhizome, 6% of alcohol processed radix angelica sinensis, 6% of salvia miltiorrhiza, 6% of processed frankincense, 6% of processed myrrh, 7% of scorpio, 5% of centipede, 6% of mud eel blood and 4% of towel gourd vegetable sponge. The preparation method comprises the following steps: preparing alcohol processed radix paeoniae alba, alcohol processed radix angelica sinensis, processed frankincense and processed myrrh by adopting the traditional method; pulverizing scorpio, centipede, mud eel blood, processed frankincense and processed myrrh together and sieving with a 120-mesh sieve for later use; watering and decocting alcohol processed radix paeoniae alba, liquorice, rhizoma atractylodis macrocephalae, isatis root, glabrous greenbrier rhizome, alcohol processed radix angelica sinensis, salvia miltiorrhiza and towel gourd vegetable sponge respectively for two times and one hour per each time, and pulverizing into fine powder; and split-charging in capsules. The preparation method has the effects of nourishing Yin, tonifying Qi, freeing channel and relieving pain, and has the advantages of no side effect, significant curative effect, and great popularization and application values.

Methods for treating neurological or neuropsychiatric diseases or disorders in humans by administering to the human a therapeutically effective dose of specific biologics are presented. The biologics of consideration include antagonists of tumor necrosis factor or of interleukin-1. The administration of these biologics is performed by specific methods, most, but not all of which fall into the category of anatomically localized administration designed for perispinal use. Anatomically localized administration involving perispinal use includes, but is not limited to the subcutaneous, intramuscular, interspinous, epidural, peridural, parenteral or intrathecal routes. Additionally, intranasal administration is discussed as a method to provide therapeutic benefit.The clinical conditions of consideration include, but are not limited to the following: diseases of the brain, including neurodegenerative diseases such as Alzheimer's Disease and Parkinson's Disease; migraine headache; spinal radiculopathy associated with intervertebral disc herniation, post-herpetic neuralgia, reflex sympathetic dystrophy, neuropathic pain, vertebral disc disease, low back pain, amyotrophic lateral sclerosis, chronic fatigue syndrome; and neuropsychiatric diseases, including bipolar affective disorder, anorexia nervosa, nicotine withdrawal, narcotic addiction, alcohol withdrawal, post-partum depression, and schizoaffective illness.

A topical medication including a therapeutically effective amount of an AMPK (adenosine monophosphate-activated protein kinase) agonist for use in the treatment of one or more the human or animal medical conditions. The medical conditions include, but are not limited to: shingles (herpes zoster), post-herpetic neuralgia (PHN), gout, migraine, trigeminal neuralgia, Complex Regional Pain Syndrome (CRPS), diabetic neuropathy, peripheral neuropathy, rheumatoid arthritis, insect-related wheals, urushiol-related rash, psoriasis, herpes simplex, atopic dermatitis (eczema), contact dermatitis, allergic dermatitis, neurotrophic ulcers, first- and second-degree burns (e.g., sunburn and chemical), fibromyalgia, rubeola, and acne. Also disclosed are a method of employing the composition and a wound dressing incorporating a therapeutically effective amount of an AMPK agonist in combination with an antimicrobial agent.

Intrathecal delivery of a pharmaceutically acceptable formulation for intrathecal administration of any drug selectively binding to this receptor to provide pain can be used in any situation in which intrathecal (“IT”) drugs are presently used for pain management. In the preferred embodiment, the drug is a triptan. In another embodiment, a combination of drugs with triptans can be used instead of just the triptan. Exemplary conditions to be treated include cancer pain, chronic back pain, post-herpetic neuralgia, and complex regional pain syndrome types I or II, as well as post-traumatic pain, diabetic vasculopathy, inflammatory radiculopathy, inflammatory plexopathies such as brachial plexopathy (Parsonage Turner syndrome), or lumbar plexopathy, HIV neuropathy, chemotherapy-induced neuropathy (such as vincristine toxicity), erythromelalgia, and inherited painful disorders such as metachromatic leukodystrophy, Friedreich's ataxia, and Fabry's disease. The triptans can also be used in acute pain management, such as in labor management or spinal blockade for surgery, where a spinal formulation of sumatriptan could be combined with traditional opiates for synergistic or additive effects.

The invention is directed to processes for synthesizing bicyclic nucleoside antiviral compounds and for synthesizing the intermediates used in the process. The invention is also directed to novel intermediate compounds useful in the process. The antiviral compounds are useful in the treatment of herpes zoster (i.e., varicella zoster virus, VZV, shingles) and for the prevention of post herpetic neuralgia (PHN) resulting from this viral infection.

The invention discloses a traditional Chinese medicine composition for treating sciatica, which comprises the following raw materials by mass: 5-20 parts of prepared common monkshood mother roots, 6-12 parts of prepared kusnezoff monkshood roots, 10-25 parts of Chinese honeylocust spine, 9-18 parts of doubleteeth pubescent angelica roots, 4-12 parts of prepared common monkshood branched roots, 6-15 parts of cassia bark, 4-18 parts of turmeric, 5-15 parts of atractylodes rhizome, 10-20 parts of coix seeds, 6-16 parts of mealy fangji roots, 6-14 parts of manchurian wildginger, 5-15 parts of twotoothed achyranthes roots, 5-16 parts of prepared frankincense, 4-15 parts of prepared myrrh, 5-14 parts of Sichuan lovage rhizome, 2-8 parts of cassia twig and 6-16 parts of liquorice roots. The composition has the effects of dispelling wind, arresting pain, promoting blood circulation and dredging collaterals, and has remarkable curative effects on various neuropathic pains such as root neuropathic pain, sciatica, trigeminal neuralgia, postherpetic neuralgia and diabetic nerve ending inflammation.

The present invention relates to extended-release pharmaceutical compositions comprising pregabalin or a salt thereof, which are adapted to release the pregabalin active ingredient according to a dual release profile. The formulations comprise two components, the first (fast ER) providing extended-release of the active ingredient in a short controlled manner lasting from about 4 to about 6 hours, and the second (slow ER or maintenance) providing extended release of the active ingredient over a period of 24 hours. The proportion of each component in the formulation may be adjusted to achieve the desired AUC and therapeutic effect following oral administration to a subject. The invention further relates to methods of using the pharmaceutical compositions for treating conditions and disorders which are responsive to pregabalin treatment, such as neuropathic pain associated with diabetic peripheral neuropathy (DPN), post herpetic neuralgia (PHN), epilepsy, seizures and fibromyalgia.

The invention discloses a pharmaceutical composition for treating neuropathic pain, which is prepared by proportionally mixing crude drugs including morin, onjisaponin A, syringopicroside and aucubin. The pharmaceutical composition can be prepared in various forms according to conventional preparation technologies. The invention overcomes the defects in the prior art and provides the pharmaceutical composition which is effective and safe in treating neuropathic pain. The pharmaceutical composition provided by the invention is simple in preparation method and low in cost. Clinical tests prove that the pharmaceutical composition has remarkable clinical effects on treating neuropathic pain such as prosopalgia, ischialgia, radiculalgia, post-herpetic neuralgia and diabetic peripheral neuritis.

The invention discloses a varicella-zoster human immunoglobulin, wherein the titer of the neutralizing antibody of the varicella-zoster virus is more than or equal to 50IU / mL, the purity of the immunoglobulin is more than or equal to 90 percent of total protein, and the content of protein is less than or equal to 180g / L. The preparation method of the varicella-zoster human immunoglobulin comprises the following steps: from blood plasma donors meeting the national blood taking standard, selecting the blood plasma of the donors, of which the titer of the neutralizing antibody IgG of the varicella-zoster virus is more than or equal to 2IU / mL and the content of protein is more than or equal to 55g / L as material blood plasmas for preparing the varicella-zoster human immunoglobulin, and mixing the obtained blood plasmas; by low-temperature ethanol or chromatography protein separation process, separating and extracting the immunoglobulin component from the obtained material blood plasmas; and processing the immunoglobulin component by the procedures of pressure filtration, chromatography, centrifuging, ultra-filtration, virus inactivation, blending, sterilization, subpackaging and the like so as to prepare the varicella-zoster human immunoglobulin. The method can be used for preparing medicaments for preventing varicella and treating post herpetic neuralgia.

The present invention relates to extended-release pharmaceutical compositions comprising pregabalin or a salt thereof, which are adapted to release the pregabalin active ingredient according to a dual release profile. The formulations comprise two components, the first (fast ER) providing extended-release of the active ingredient in a short controlled manner lasting from about 4 to about 6 hours, and the second (slow ER or maintenance) providing extended release of the active ingredient over a period of 24 hours. The proportion of each component in the formulation may be adjusted to achieve the desired AUC and therapeutic effect following oral administration to a subject. The invention further relates to methods of using the pharmaceutical compositions for treating conditions and disorders which are responsive to pregabalin treatment, such as neuropathic pain associated with diabetic peripheral neuropathy (DPN), post herpetic neuralgia (PHN), epilepsy, seizures and fibromyalgia.

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of fibromyalgia pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, bipolar depression, stress, cancer pain, and lower back pain.

The present invention provides a tablet for treating postherpetic neuralgia and a method of treating postherpetic neuralgia with the use of the tablet. The therapeutic tablet for postherpetic neuralgia according to the present invention is characterized in comprising buprenorphine hydrochloride, having a double layer structure consisting of a quick-release layer and a sustained-release layer, wherein the tablet is adhesive to the oral mucosa.